long intergenic non-protein coding RNA 993Genealiases: []
Q-omics provides the consensus-scored LINC00993 profile across patient tissues and cancer cell-line models. LINC00993 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC00993 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, LINC00993 RNA expression shows 7,762 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, HNSC, and BRCA as cancer lineages where LINC00993 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00993 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00993 survival associations across molecular data types. LINC00993 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00993 RNA expression–survival associations across cancer types. High LINC00993 expression shows unfavorable associations in ACC, KIRC, LUAD and OV, but favorable associations in BRCA and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC00993 RNA expression.
This table summarizes LINC00993 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00993. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00993 shows lower tumor expression in KIRC and higher tumor expression in HNSC, KICH and BLCA. The HNSC box plot shows higher LINC00993 RNA expression in tumor versus normal tissue (log2 FC = +0.112, t-test p = .006).
This table shows molecular features associated with LINC00993 in patient tissues and cancer cell lines. In patient samples, LINC00993 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
